Impact of Pharmacist in Cardiology Service

Cardiomyopathy, Diabetic Clinical Trial

Official title:

Presence of a Clinical Pharmacist in a Cardiology Department: What Impact on the Management of Diabetic Patients Within Care Pathways? Example of Inpatient Cardiac Patients at GHPSJ

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03206294
• Other study ID #: PhCardiab
• Status: Completed
• Phase: N/A
• Start date: March 8, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: August 2018
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The coverage of the diabetes is a multidisciplinary care, with practitioners' implication(hospital and liberal), and other medical and paramedical profession: doctor, pharmacist, male nurse, nutritionist, etc. In fact there is a real importance of link between hospital and general medecine outside. That's why the pharmacist's presence during the hospitalization seems to be a good alternative to make the link between hospital and the outside pharmacist where patient take his treatment.

Hospital pharmacis proceed to a treatment conciliation at the entrance and at discharge.

By this conciliation the aim of the study is to show and quantify the impact of pharmacist presence on therapeutic target .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: December 31, 2018
• Est. primary completion date: April 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diabetes type 2 patient hospitalized in cardiology service

• Hospitalization more than 24 hours

• with insuline or/and oral anti diabetic

Exclusion Criteria:

• diabètes type 1

• iatrogenic hyperglycaemia

• hospitalization for cardia angiography

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Diabetic
• Diabetic Cardiomyopathies

Intervention

Other:
• pharmacist assessment
St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of biological test glycosylated haemoglobin evolution between the entrance and discharge		5 days